Topiramate Tablet, Film Coated
Product Images NDC 0615-8595

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 0615-8595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Topiramate 8593 8594 8595 1)

Chemical Structure (Topiramate 8593 8594 8595 1)
Chemical structure diagram of Topiramate, showing its molecular composition and bonding arrangement as depicted in the image.*
FDA Label Image

Figure 1: Kaplan-meier Estimates Of Cumulative Rates For Time To First Seizure (Topiramate 8593 8594 8595 2)

Figure 1: Kaplan-meier Estimates Of Cumulative Rates For Time To First Seizure (Topiramate 8593 8594 8595 2)
A line chart showing cumulative rates for time to first seizure over 500 days comparing Topiramate 50 mg/day (N=234) and Topiramate 400 mg/day (N=236). The Y-axis represents cumulative rates, and the X-axis shows time in days. The graph includes a p-value of 0.0002, indicating statistical comparison between the two doses.*
FDA Label Image

Figure 2 (Topiramate 8593 8594 8595 3)

Figure 2 (Topiramate 8593 8594 8595 3)
A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate for Placebo, Topiramate 50 mg/day, 100 mg/day, and 200 mg/day groups. The chart includes data from two studies, Study 11 and Study 12, with error bars showing variability and significance levels indicated for certain groups.*
FDA Label Image

Principal Display Panel (Topiramate 8593 8594 8595 4)

Principal Display Panel (Topiramate 8593 8594 8595 4)
Label for Topiramate Tablets USP 25 mg, film-coated oral tablets. The label indicates a quantity of 30 tablets, manufactured by Aurobindo and packaged by Vangard Labs, Glasgow, KY. Barcode and lot number 8593 are shown, with storage instructions and institutional use notice.*
FDA Label Image

Principal Display Panel (Topiramate 8593 8594 8595 5)

Principal Display Panel (Topiramate 8593 8594 8595 5)
Label for Topiramate Tablets USP 50 mg film-coated oral tablets shows supply quantity of 30 tablets. Manufactured by Aurobindo and packaged by Vangard in Glasgow, KY. Label includes lot number 8594, barcode, storage instructions (20° to 25°C), and statement for institutional use only. Multiple small labels with identical product and packaging details are visible for individual tablet identification.*
FDA Label Image

Principal Display Panel (Topiramate 8593 8594 8595 6)

Principal Display Panel (Topiramate 8593 8594 8595 6)
Topiramate Tablets USP 100 mg film-coated oral tablets labeling for institutional use only. The label includes storage instructions, dosage form, and manufacturer details indicating packaging by Vangard Labs, Glasgow, KY. The page features multiple barcodes and lot number 8595 for inventory tracking.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.